Comparative Analysis of Simian Immunodeficiency Virus Gag-Specific Effector and Memory CD8+ T Cells Induced by Different Adenovirus Vectors

ABSTRACT Adenovirus (Ad) vectors are widely used as experimental vaccines against several infectious diseases, but the magnitude, phenotype, and functionality of CD8+ T cell responses induced by different adenovirus serotypes have not been compared. To address this question, we have analyzed simian immunodeficiency virus Gag-specific CD8+ T cell responses in mice following vaccination with Ad5, Ad26, and Ad35. Our results show that although Ad5 is more immunogenic than Ad26 and Ad35, the phenotype, function, and recall potential of memory CD8+ T cells elicited by these vectors are substantially different. Ad26 and Ad35 vectors generated CD8+ T cells that display the phenotype and function of long-lived memory T cells, whereas Ad5 vector-elicited CD8+ T cells are of a more terminally differentiated phenotype. In addition, hepatic memory CD8+ T cells elicited by Ad26 and Ad35 mounted more robust recall proliferation following secondary challenge than those induced by Ad5. Furthermore, the boosting potential was higher following priming with alternative-serotype Ad vectors than with Ad5 vectors in heterologous prime-boost regimens. Anamnestic CD8+ T cell responses were further enhanced when the duration between priming and boosting was extended from 30 to 60 days. Our results demonstrate that heterologous prime-boost vaccine regimens with alternative-serotype Ad vectors elicited more functional memory CD8+ T cells than any of the regimens containing Ad5. In summary, these results suggest that alternative-serotype Ad vectors will prove useful as candidates for vaccine development against human immunodeficiency virus type 1 and other pathogens and also emphasize the importance of a longer rest period between prime and boost for generating optimal CD8+ T cell immunity.

[1]  D. Barouch,et al.  Alternative Serotype Adenovirus Vaccine Vectors Elicit Memory T Cells with Enhanced Anamnestic Capacity Compared to Ad5 Vectors , 2012, Journal of Virology.

[2]  P. Abbink,et al.  Adenovirus serotype 26 utilizes CD46 as primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys , 2012, Journal of Virology.

[3]  Jerome H. Kim,et al.  Vaccine Protection Against Acquisition of Neutralization-Resistant SIV Challenges in Rhesus Monkeys , 2011, Nature.

[4]  S. Swift,et al.  Optimizing vaccine-induced CD8+ T-cell immunity: focus on recombinant adenovirus vectors , 2011, Expert review of vaccines.

[5]  K. Mansfield,et al.  International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. , 2011, Vaccine.

[6]  M. Hudgens,et al.  Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys , 2011, Science Translational Medicine.

[7]  L. Harrington,et al.  Cytokines and the inception of CD8 T cell responses. , 2011, Trends in immunology.

[8]  Matthew S. Lewis,et al.  Profound early control of highly pathogenic SIV by an effector-memory T cell vaccine , 2011, Nature.

[9]  C. Alam,et al.  Ly6C supports preferential homing of central memory CD8+ T cells into lymph nodes , 2011, European journal of immunology.

[10]  Joshua C. Johnson,et al.  Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus Challenge , 2011, Journal of Virology.

[11]  R. Ahmed,et al.  From vaccines to memory and back. , 2010, Immunity.

[12]  D. Kaufman,et al.  Route of Adenovirus-Based HIV-1 Vaccine Delivery Impacts the Phenotype and Trafficking of Vaccine-Elicited CD8+ T Lymphocytes , 2010, Journal of Virology.

[13]  J. Kohlmeier,et al.  Migration, maintenance and recall of memory T cells in peripheral tissues , 2009, Nature Reviews Immunology.

[14]  D. Masopust Developing an HIV cytotoxic T‐lymphocyte vaccine: issues of CD8 T‐cell quantity, quality and location , 2009, Journal of internal medicine.

[15]  Devan V Mehrotra,et al.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial , 2008, The Lancet.

[16]  D. Montefiori,et al.  Immune Control of an SIV Challenge by a T Cell-Based Vaccine in Rhesus Monkeys , 2008, Nature.

[17]  Y. Liu,et al.  Comparison of adenoviruses from species B, C, E, and F after intravenous delivery. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  N. Letvin,et al.  The Impact of a Boosting Immunogen on the Differentiation of Secondary Memory CD8+ T Cells , 2007, Journal of Virology.

[19]  E. Wherry,et al.  Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. , 2007, Blood.

[20]  K. Mansfield,et al.  Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D , 2007, Journal of Virology.

[21]  Sang-Jun Ha,et al.  Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination. , 2006, Journal of immunology.

[22]  Jiang Fan,et al.  Vaccine-Induced Cellular Immune Responses Reduce Plasma Viral Concentrations after Repeated Low-Dose Challenge with Pathogenic Simian Immunodeficiency Virus SIVmac239 , 2006, Journal of Virology.

[23]  K. Mansfield,et al.  Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity , 2006, Nature.

[24]  J. Bramson,et al.  The CD8+ T Cell Population Elicited by Recombinant Adenovirus Displays a Novel Partially Exhausted Phenotype Associated with Prolonged Antigen Presentation That Nonetheless Provides Long-Term Immunity1 , 2006, The Journal of Immunology.

[25]  Alan D. Roberts,et al.  Differential contributions of central and effector memory T cells to recall responses , 2005, The Journal of experimental medicine.

[26]  S. Kostense,et al.  Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity1 , 2004, The Journal of Immunology.

[27]  Antonio Lanzavecchia,et al.  Central memory and effector memory T cell subsets: function, generation, and maintenance. , 2004, Annual review of immunology.

[28]  H. Mizuguchi,et al.  Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[29]  A. Gaggar,et al.  CD46 is a cellular receptor for group B adenoviruses , 2003, Nature Medicine.

[30]  Rustom Antia,et al.  Lineage relationship and protective immunity of memory CD8 T cell subsets , 2003, Nature Immunology.

[31]  M. Tsuji,et al.  Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[32]  L. Lefrançois,et al.  Preferential Localization of Effector Memory Cells in Nonlymphoid Tissue , 2001, Science.

[33]  D. Brough,et al.  The Coxsackievirus-Adenovirus Receptor Protein Can Function as a Cellular Attachment Protein for Adenovirus Serotypes from Subgroups A, C, D, E, and F , 1998, Journal of Virology.

[34]  J. Altman,et al.  Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. , 1998, Immunity.

[35]  L. Philipson,et al.  HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Bergelson,et al.  Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5 , 1997, Science.

[37]  Philip J. R. Goulder,et al.  Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.

[38]  David Gray,et al.  Immunological Memory and Protective Immunity: Understanding Their Relation , 1996, Science.

[39]  Yonghong,et al.  The CD8 T Cell Population Elicited by Recombinant Adenovirus Displays a Novel Partially Exhausted Phenotype Associated with Prolonged Antigen Presentation That Nonetheless Provides Long-Term Immunity , 2005 .